India’s medical and wellness tourism industry is expected to grow from $18.2 billion in 2025 to $58.2 billion by 2035, according to a new report jointly released by the Federation of Hotel and Restaurant Associations of India (FHRAI) and KPMG India. Titled “Heal in India: Catalysing Medical and Wellness Tourism for a Healthier Global Future”, the report was unveiled at the Heal in India...

DeepMind has launched a powerful new AI model, AlphaGenome, that promises to transform how scientists understand the human genome—especially the mysterious non-coding regions long dubbed DNA’s “dark matter.” The model can predict how single DNA variants affect gene regulation across the genome, enabling researchers to better link genetic mutations to diseases such as cancer. A milestone in understanding gene regulation AlphaGenome stands apart from earlier models...

Global biopharmaceutical leader AstraZeneca has inaugurated a new ₹166 crore Global Hub in Bengaluru, focused on scaling AI-powered healthcare solutions across its global operations. This facility marks a key expansion in the company’s India footprint and reinforces its commitment to patient-centric innovation. Strengthening India's role in global R&D and digital health The Bengaluru hub is designed to accommodate nearly 1,300 employees, including the creation of 400...

Seqrite, the enterprise security arm of Quick Heal Technologies, has released its India Cyber Threat Report 2025, revealing that healthcare organisations accounted for 21.82% of all cyberattacks in the country during 2024—more than any other sector. The report highlights that India’s rapidly digitising healthcare landscape, with its high volume of sensitive patient data and mission-critical systems, has become a primary target for cybercriminals. Seqrite researchers...

The Uttar Pradesh government is advancing a major pharmaceutical manufacturing initiative in Lalitpur, aiming to position the state alongside Gujarat and Andhra Pradesh as a national hub for bulk drugs and active pharmaceutical ingredients (APIs). Backed by a projected investment of over ₹12,000 crore, the Lalitpur pharma park is being developed on a 1,472-acre site, with 353 acres already under development in Phase I. The...

The Indian pharmaceutical market (IPM) registered a year-on-year growth of 7.4% in April 2025, largely propelled by chronic therapies such as cardiac, central nervous system (CNS), and respiratory treatments, according to a report by Motilal Oswal Financial Services. Chronic and specialty therapies fuel performance Cardiac, CNS, and respiratory segments significantly outperformed in April, pushing overall market growth despite the seasonal nature of acute therapies. Respiratory therapies,...

The Tata Memorial Centre (TMC) has entered into a partnership with GE HealthCare Technologies to launch a dedicated Cancer Research and Innovation Centre in India. The collaboration, formalised through a memorandum of understanding (MoU) signed on Wednesday, is aimed at driving advancements in cancer diagnosis, treatment, and research. GE HealthCare will act as the technology partner, bringing in advanced medical technologies, while TMC will serve...

Mumbai-based Micro Life Sciences Pvt Ltd is preparing to raise $250–300 million in fresh capital ahead of its planned initial public offering (IPO), with investments led by Singapore’s Temasek Holdings and the Abu Dhabi Investment Authority (ADIA). The fundraise, comprising both primary and secondary share sales, is expected to push the company’s valuation beyond $1.8 billion. This round marks a significant step in the company’s...

India’s orthopaedic and cardiac implant sector is expected to grow significantly, reaching a market size of USD 4.5 to 5 billion by FY2027–28, according to a new report by CareEdge Ratings. This marks a substantial rise from the estimated USD 2.4 to 2.7 billion recorded in FY24, and reflects a compound annual growth rate (CAGR) of 15–16%. The growth is being driven by several demand-side...

India has formally declined the United Kingdom’s demand to include a ‘data exclusivity’ provision in the recently concluded free trade agreement (FTA), reaffirming its commitment to the domestic generic pharmaceutical industry. Officials confirmed that the clause was discussed during negotiations, but the Indian side refused to accept any terms that would restrict the ability of generic manufacturers to operate. Data exclusivity refers to the protection...